Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272935
Status:
COMPLETED
Last Update Posted:
2012-07-03
First Post:
2006-01-04
Brief Title:
A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 03 mg for the Treatment of Hot Flashes
Sponsor:
Duramed Research
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Randomized Multicenter Double-blind Placebo-controlled Trial to Demonstrate the Safety and Efficacy of Daily 03 mg Synthetic Conjugated Estrogens A Cenestin for the Treatment of Vasomotor Symptoms in Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind study to compare the efficacy and safety of daily doses of Cenestin 03 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women
Detailed Description:
The overall study duration will be approximately 16 weeks After a screeningbaseline period of up to 4 weeks patients will be randomized to receive either placebo tablets or Cenestin 03mg tablets
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None